Elekta AB ser. B fell 4.2% to trade at 51.78 after the Swedish medical technology company released its first-quarter 2026/27 interim report early this morning. The results showed only modest growth in constant-currency net sales of around 3%, but profitability disappointed investors as margins contracted.
The company attributed the margin decline to unfavorable foreign exchange effects and the continued impact of tariffs. Those factors raised fresh concerns among market participants about how quickly Elekta can restore earnings momentum.
Two of Elekta’s strategically important regions - the U.S. and China - remained soft in the quarter. Management and market commentary in the report suggested that a meaningful recovery in China is not expected until the second half of the fiscal year, leaving near-term revenue and margin recovery prospects constrained.
Analyst sentiment heading into the interim release was already tilted toward the negative, reducing tolerance for any shortfall. Danske Bank held a Sell rating with a SEK 45 price target, UBS initiated coverage with a Sell and a SEK 34 target, and Barclays maintained an Underweight stance. That consensus positioned the stock to react sharply to weaker-than-expected profitability metrics.
The broader market provided no offset to the company-specific weakness. U.S. indices were modestly positive on the day and global risk appetite was broadly stable, indicating that Elekta’s decline was driven by the company’s earnings dynamics rather than a wider market downturn.
The share reaction mirrors prior volatility around results. The company’s Q4 2026 report in May prompted a one-day drop of more than 14%, and investors remain sensitive to signs that the turnaround is taking longer than anticipated.
On the trading session, Elekta opened at 55.08 and moved down to a session low of 51.78. That closing level leaves the stock appreciably closer to its 52-week low of 42.2 than to its 52-week high of 66.6.
Market snapshot:
- Intraday decline: -4.2% to 51.78
- Constant-currency net sales: approximately +3%
- Key near-term catalyst: meaningful China recovery expected in second half of fiscal year